Teriparatide is a lab-made version of the first 34 amino acids of parathyroid hormone (PTH). Given as a daily injection, sold first as Forteo, it builds new bone rather than only slowing bone loss, which makes it an osteoanabolic drug for people with osteoporosis at high risk of fracture.
The daily shot is its main drawback, and two lines of work aim to change that. Entera Bio is developing EB613, an oral tablet form of PTH(1-34); at ENDO 2026 in June it reported that a single tablet gave drug levels and bone responses comparable to Forteo, ahead of a planned 750-patient Phase 3 trial. In October 2026, Shandong University chemists reported fatty-acid versions of teriparatide that matched its bone effects in animals and lasted longer in blood.
See #osteoporosis and our guide to peptides for osteoporosis.
Researchers at Shandong University and the Shandong Academy of Pharmaceutical Science reported in the Journal of Medicinal Chemistry on October 16, 2026 that they used a site-specific chemical ligation method to attach fatty acids of different lengths to teriparatide, the bone-building osteoporosis drug that must be injected daily. Of 12 lipidated versions, four matched native teriparatide's bone-building activity in lab and animal tests, and the lead compound, called 62, was markedly more stable in serum. The goal is a longer-acting osteoporosis injection; the work is preclinical.
Entera Bio (Nasdaq: ENTX) presented full single-tablet EB613 results on June 14 at ENDO 2026 in Chicago as a late-breaking oral. The single-tablet EB613 achieved a comparable pharmacokinetic and pharmacodynamic profile to Forteo (injectable teriparatide) and to the multi-tablet EB613 used in Entera's earlier Phase 2 study in postmenopausal women with osteoporosis. On the administration-experience quality-of-life questionnaire, 14 of 15 study participants preferred the single tablet to the multi-tablet format, and all 15 preferred the daily oral EB613 to the daily injection. Entera plans to advance the single-tablet formulation into the Phase 3 trial in 750 postmenopausal women starting late 2026, with topline expected H2 2028.
Entera Bio (Nasdaq: ENTX) confirmed that its first-in-class oral PTH(1-34) tablet EB613 was selected for a late-breaking oral presentation at ENDO 2026 covering single-tablet data ahead of the 750-patient Phase 3 trial set to start late 2026 in postmenopausal osteoporosis. EB613 applies Entera's N-Tab oral-peptide delivery platform to teriparatide (the active ingredient in Forteo). On the obesity side, Entera will present preclinical PK/PD data on EB618, a first-in-class oral dual GLP-1/glucagon receptor agonist, in non-human primates on Saturday June 13 12:15-1:45 PM CT. The ENDO slot extends Entera's spring narrative beyond the Q1 2026 Phase 3 plan first disclosed in May.